AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients
Adrian Daly(Centre Hospitalier Universitaire de Liège), Albert Beckers(Centre Hospitalier Universitaire de Liège), Emanuel Christ(University of Basel), Catherine Waeber Stephan, Chiara Villa(Centre National de la Recherche Scientifique), Liliya Rostomyan(Inserm), Beatrice Waser, Daniela Betea(Centre Hospitalier Universitaire de Liège), Natalia S. Pellegata(University of Pavia), Jean–Claude Reubi(University of Bern), Jean‐François Bonneville(Centre Hospitalier Universitaire de Liège)
Cited by 62
Related Papers
The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors
|Endocrine Reviews|1991|814
Clinical Characteristics and Therapeutic Responses in Patients with Germ-Line<i>AIP</i>Mutations and Pituitary Adenomas: An International Collaborative Study
|The Journal of Clinical Endocrinology & Metabolism|2010|374
A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update
|The Journal of Clinical Endocrinology & Metabolism|2019|363
From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal
|Endocrine Related Cancer|2017|357
Gigantism and Acromegaly Due to Xq26 Microduplications and <i>GPR101</i> Mutation
|New England Journal of Medicine|2014|340